Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data.
Saved in:
| Title: | Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data. |
|---|---|
| Authors: | Reimann P; Department of Internal Medicine II, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.; Private University of the Principality of Liechtenstein, Triesen, Principality of Liechtenstein., Mavroeidi IA; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; German Cancer Consortium (DKTK), Partner Site Essen, a partnership between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany.; Bridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Burghofer J; Laboratory for Molecular Genetic Diagnostics, Ordensklinikum Linz, Linz, Austria., Taghizadeh H; Department of Internal Medicine I, Universitätsklinikum St. Pölten, St. Pölten, Austria., Webersinke G; Laboratory for Molecular Genetic Diagnostics, Ordensklinikum Linz, Linz, Austria., Kasper S; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; German Cancer Consortium (DKTK), Partner Site Essen, a partnership between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany., Schreil G; Department of Internal Medicine, State Hospital Pyhrn Eisenwurzen, Steyr, Austria., Morariu D; Department of Internal Medicine, State Hospital Wiener Neustadt, Wiener Neustadt, Austria., Reichinger A; Department of Internal Medicine I for Hematology With Stem Cell Transplantation, Hemostaseology, and Medical Oncology, Ordensklinikum Linz, Linz, Austria., Baba HA; German Cancer Consortium (DKTK), Partner Site Essen, a partnership between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany.; Institute of Pathology, West German Cancer Center, University Hospital Essen, Essen, Germany., Kirchweger P; Medical Faculty, Johannes Kepler University Linz, Linz, Austria.; Department of General and Visceral Surgery, Ordensklinikum Linz, Linz, Austria.; Gastrointestinal Cancer Center, Ordensklinikum Linz, Linz, Austria., Schuler M; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany.; German Cancer Consortium (DKTK), Partner Site Essen, a partnership between German Cancer Research Center (DKFZ) and University Hospital Essen, Essen, Germany.; National Center for Tumor Diseases (NCT) West, Campus Essen, Essen, Germany., Djanani A; Department of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria., Prager GW; Department of Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria., Rumpold H; Department of Internal Medicine I for Hematology With Stem Cell Transplantation, Hemostaseology, and Medical Oncology, Ordensklinikum Linz, Linz, Austria.; Medical Faculty, Johannes Kepler University Linz, Linz, Austria.; Gastrointestinal Cancer Center, Ordensklinikum Linz, Linz, Austria., Benda M; Department of Internal Medicine II, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.; Private University of the Principality of Liechtenstein, Triesen, Principality of Liechtenstein., Schneider EM; Department of Internal Medicine II, Academic Teaching Hospital Feldkirch, Feldkirch, Austria., Mink S; Private University of the Principality of Liechtenstein, Triesen, Principality of Liechtenstein.; Central Medical Laboratories, Feldkirch, Austria., Winder T; Department of Internal Medicine II, Academic Teaching Hospital Feldkirch, Feldkirch, Austria.; University of Zurich, Zurich, Switzerland., Doleschal B; Department of Internal Medicine I for Hematology With Stem Cell Transplantation, Hemostaseology, and Medical Oncology, Ordensklinikum Linz, Linz, Austria. bernhard.doleschal@ordensklinikum.at.; Medical Faculty, Johannes Kepler University Linz, Linz, Austria. bernhard.doleschal@ordensklinikum.at. |
| Source: | Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Oct 03; Vol. 73 (12), pp. 251. Date of Electronic Publication: 2024 Oct 03. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0851 |
|---|---|
| DOI: | 10.1007/s00262-024-03842-y |
